AMNI Stock Overview
Amniotics AB (publ) develops stem cell-based therapeutics to treat severe life-threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Amniotics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.0036 |
| 52 Week High | kr0.15 |
| 52 Week Low | kr0.0022 |
| Beta | 0.54 |
| 1 Month Change | -2.70% |
| 3 Month Change | -53.85% |
| 1 Year Change | -96.68% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| AMNI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -7.7% | 2.3% | 2.8% |
| 1Y | -96.7% | 0.2% | 13.6% |
Return vs Industry: AMNI underperformed the Swedish Biotechs industry which returned 0.2% over the past year.
Return vs Market: AMNI underperformed the Swedish Market which returned 13.6% over the past year.
Price Volatility
| AMNI volatility | |
|---|---|
| AMNI Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: AMNI's share price has been volatile over the past 3 months.
Volatility Over Time: AMNI's weekly volatility has decreased from 33% to 15% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 6 | Marcus Larsson | www.amniotics.com |
Amniotics AB (publ) develops stem cell-based therapeutics to treat severe life-threatening diseases. The company’s lead drug candidate is PulmoStem for the treatment of lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; CutiStem for the treatment of dermatological indications; and AMNI-NK003.
Amniotics AB (publ) Fundamentals Summary
| AMNI fundamental statistics | |
|---|---|
| Market cap | kr9.84m |
| Earnings (TTM) | -kr30.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs AMNI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMNI income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr30.87m |
| Earnings | -kr30.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 20, 2024
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AMNI perform over the long term?
See historical performance and comparison